Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Snake venom serine proteinases are glycosylated enzymes found primarily in the venoms of Viperidae family snakes, with some presence in Elapidae and Colubridae families[1][2]. These enzymes belong to the chymotrypsin-like serine protease superfamily and are classified within the PA clan and S1 family[2]. They contain the highly conserved catalytic triad consisting of His57, Asp102, and Ser195[1][3]. SVSPs are among the best-characterized proteins in snake venom and evolved from a kallikrein-like serine protease that emerged with the Toxicofera clade, which includes snakes and certain lizards[2]. Despite showing high sequence similarity across species, particularly in their signal peptides and untranslated regions, the mature protein sequences show considerable diversity, allowing for varied substrate specificities[1]. These enzymes are multifunctional and act on various stages of the prey's hemostatic system[2]. The most commonly described activity is thrombin-like function, where they cleave fibrinogen to produce fibrin, though unlike true thrombin, they do not activate factor XIII and are not inhibited by heparin[3]. SVSPs can also function as kallikrein-like enzymes, platelet aggregators, and activators of plasminogen, factor X, factor V, prothrombin, and protein C[2]. Many enzymes can act on multiple substrates, producing either pro-coagulant or anti-coagulant effects[2]. Structurally, SVSPs contain 12 conserved cysteine residues forming disulfide bonds, N-terminal signal peptides (typically 18 amino acids), and activation peptides (typically 6 amino acids)[1]. They are predicted to be N-glycosylated, which increases their molecular mass beyond what would be predicted from amino acid sequence alone[1]. Interestingly, some SVSPs have mutations in their catalytic triad residues and are termed serine protease homologues. These variants may lack classical enzymatic activity but could have evolved alternative toxic functions[1]. The evolution of SVSP diversity appears to involve multiple mechanisms including accelerated evolution at the amino acid level, alternative splicing, and accelerated segment switching in specific surface regions[1]. SVSPs have significant biotechnological potential as diagnostic reagents, antithrombotic agents, and tools for understanding hemostasis mechanisms[3]. Their ability to affect multiple aspects of the coagulation cascade makes them valuable for both research and potential therapeutic applications[2].
Snake venom serine proteinases act through multiple mechanisms including thrombin-like activity (cleaving fibrinogen α and β chains to form fibrin), kallikrein-like activity, plasminogen activation, factor X activation, factor V activation, prothrombin activation, and protein C activation. They can exhibit both pro-coagulant and anti-coagulant effects depending on the specific substrate recognized.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Snake venom serine proteinase (SVSP).